Dublin, Feb. 03, 2022 (GLOBE NEWSWIRE) -- The "Global Genomic Biomarker Market 2021-2027" report has been added to ResearchAndMarkets.com's offering.
The global genomics biomarker market is projected to exhibit a CAGR of over 15% during the forecast period. Genomic biomarkers is a field of science that aims for the collective characterization and quantification of genes. Genomics additionally includes the sequencing and analysis of genomes using high-throughput DNA sequencing and bioinformatics for assembling and analyzing the function and structure of entire genomes.
Major factors contributing to the growth of the market include the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, neurological disorders, and others. Other driving factors include increasing research and investment in the field of genomic biomarkers and the use of genomic biomarker services for the enhancement of drug development pipelines.
However, some factors are restraining the market growth that includes reimbursement challenges and limited market capabilities in underdeveloped markets. Genomic biomarkers in the development of personalized medicine and rising demand from emerging economies are the factors to create opportunities for the market across the globe.
Segmental Outlook
The global genomic biomarker market is segmented on the basis of disease indication and end-user. By disease indication, the market is segmented into oncology, cardiology, neurology, and others. By end-user, the market is segmented into hospitals and diagnostic and research laboratories.
Among disease indications, oncology contributed a significant share in 2019. The segmental growth is attributed to the high demand for genomic biomarkers in oncology owing to the rise in the prevalence of cancer and an increasing number of research efforts towards genomic biomarkers for cancer detection and understanding therapeutic responses for individual patients.
Regional Outlooks
Geographically, the global genomic biomarker market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World. North America contributed a prominent share in the global genomic biomarker market. Factors contributing to the market growth include the presence of well-developed healthcare infrastructure, high healthcare R& D investments, high healthcare expenditure, and others. Europe is another significant market and holds a considerable market share in the global genomic biomarker market.
Market Players Outlook
Some of the key players of the genomic biomarker market include Agilent Technologies, Inc., Illumina, Inc., Myriad Genetics, Inc., Thermo Fischer Scientific, Inc., Genomic Health Inc., Bio-Rad Laboratories Inc., Second Genomic Therapeutics, and Hologic, Inc. In order to survive in the market, these players adopt different marketing strategies such as a merger and acquisitions, product launch, and geographical expansion.
For instance, in 2020, Gilead Sciences, Inc. and Second Genome announced their four-year strategic collaboration to identify biomarkers associated with clinical response and to identify new potential targets and drug candidates for the treatment of IBD (inflammatory bowel disease).
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Genomic biomarker market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying 'who-stands-where' in the market.
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Genomic Biomarker Market By Disease Indication
5.1.1. Oncology
5.1.2. Cardiology
5.1.3. Neurology
5.1.4. Others
5.2. Global Genomic Biomarker By End-Users
5.2.1. Hospitals
5.2.2. Diagnostic And Research Laboratories
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. 23andMe
7.2. Acobiom SAS
7.3. Agilent Technologies Inc.
7.4. Almac Group
7.5. Banyan Biomarkers, Inc.
7.6. Bio-Rad Laboratories, Inc.
7.7. BioMerieux S.A.
7.8. Celgene Corp.
7.9. Cofactor Genomics, Inc
7.10. Destina Genomics Ltd
7.11. DNAVision SA
7.12. Eagle Genomics Ltd.
7.13. Empire Genomics, LLC
7.14. Enzo Life Sciences, Inc.
7.15. Epigenomics AG
7.16. Eurofins Scientific SE
7.17. Foundation Medicine, Inc.
7.18. GeneNews Ltd.
7.19. Genomic Health, Inc.
7.20. Hologic, Inc.
7.21. Human Longevity, Inc.
7.22. Illumina, Inc
7.23. Insight Genetics Inc.
7.24. Integragen SA
7.25. Liquid Genomics, Inc.
7.26. Luminex Corp.
7.27. Merck KGaA
7.28. Myriad Genetics Inc.
7.29. NeoGenomics Laboratories, Inc.
7.30. New England Biolabs Inc.
7.31. Origene Technologies, Inc.
7.32. Otsuka Pharmaceutical Co., Ltd.
7.33. Pfizer Inc.
7.34. Pliant Therapeutics, Inc.
7.35. Second Genomic Therapeutics
7.36. Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/o9116i
